Selected neurologic disorders related to polycystic ovary syndrome

Ginekologia Polska

Volumn 83, Issue 2, 2012, Pages 128-131

  Krȩpuła, Katarzyna ^a   Bidzińska Speichert, Bozena ^b   Lenarcik, Agnieszka ^b   Tworowska Bardzińska, Urszula ^a  

^a Endocrinology Outpatient Clinic   (Poland)

^b UNIVERSITY OF WROC AW   (Poland)

Author keywords

Epilepsy; PCOS; Valproic acid

Indexed keywords

ANAMNESIS; COMORBIDITY; EPIDEMIOLOGY; EPILEPSY; FEMALE; HUMAN; MENSTRUATION DISORDER; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PREGNANCY; REVIEW; RISK FACTOR; WOMEN'S HEALTH;

CAUSALITY; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; MEDICAL HISTORY TAKING; MENSTRUATION DISTURBANCES; OLIGOMENORRHEA; POLYCYSTIC OVARY SYNDROME; PREGNANCY; RISK FACTORS; WOMEN'S HEALTH;

EID: 84861503935     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Azziz R, Carmina E, Dewailly D, [et al.]. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006, 91, 4237-4245.
2. Banerjee P, Filippi D, Allen Hauser W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009, 85, 31-45.
3. Herzog A. Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure. 2008, 17, 101-110.
4. Bauer J, Isojärvi J, Herzog A, [et al.]. Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry. 2002, 73, 121-125.
5. Morrell M J, Montouris G. Reproductive disturbances in patients with epilepsy. Cleve Clin J Med. 2004, 71, Suppl 2, 19-24.
6. Harden C. Polycystic ovaries and polycystic ovary syndrome in epilepsy: evidence for neurogonadal disease. Epilepsy Curr. 2005, 5, 142-146.
7. Bilo L, Meo R, Valentino R, [et al.]. Characterization of reproductive endocrine disorder in women with epilepsy. J Clin Endocrinol Metab. 2001, 86, 2950-2956.
8. Nelson-DeGrave V, Wickenheisser J, Cockrell J. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology. 2004, 145, 799-808.
9. Joffe H, Hayes F. Menstrual cycle dysfunction associated with neurologic and psychiatric disorders: their treatment in adolescents. Ann N Y Acad Sci. 2008, 1135, 219-229.
10. Morrell M, Giudice L, Flynn K, [et al.]. Predictors of ovulatory failure in women with epilepsy. Ann Neurol. 2002, 52, 704-711.
11. Scharfman H, Kim M, Hintz T, [et al.]. Seizures and reproductive function: insights from female rats with epilepsy. Ann Neurol. 2008, 64, 687-697.
12. Laforet G, Apostol G, Robieson W, [et al.]. Reproductive endocrine effects of divalproex sodium extended-release in adolescent females. In: Child Neurology Society, 2007, 36th Annual Meeting: Quebec City, Canada.
13. Verrotti A, la Torre R, Trotta D, [et al.]. Valproate-induced insulin resistance and obesity in children. Horm Res. 2009, 71, 125-131.
14. Wood J, Nelson-Degrave V, Jansen E, [et al.]. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics. 2005, 20, 233-243.
15. Göttlicher M, Minucci S, Zhu P, [et al.]. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20, 6969-6978.
16. Lakhanpal D, Kaur G. Valproic acid alters GnRH-GABA interactions in cycling female rats. Cell Mol Neurobiol. 2007, 27,1069-1083.
17. Lagace D, McLeod R, Nachtigal M. Valproic acid inhibits leptin secretion and reduces leptin messenger ribonucleic acid levels in adipocytes. Endocrinology. 2004, 145, 5493-5503.
18. Qiao L, Schaack J, Shao J. Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology. 2006, 147, 865-874.
19. Isojärvi J, Laatikainen T, Knip M, [et al.]. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996, 39, 579-584.
20. Luef G, Abraham I, Trinka E, [et al.]. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res. 2002, 48, 91-102.
21. Pylvänen V, Knip M, Pakarinen A, [et al.]. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia. 2002, 43, 514-517.
22. Pylvänen V, Pakarinen A, Knip M, [et al.]. Characterisation of insulin secretion in valproatetreated patients with epilepsy. Epilepsia. 2006, 47, 1460-1464.
23. Luef G, Abraham I, Hoppichler F, [et al.]. Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism. 2002, 51, 1274-1278.
24. Wong H, Chu T, Lai J, [et al.]. Sodium valproate inhibits glucose transport and exacerbates Glut1-deficiency in vitro. J Cell Biochem. 2005, 96, 775-785.
25. Luef G, Lechleitner M, Bauer G, [et al.]. Valproic acid modulates islet cell insulin secretion: a possible mechanism of weight gain in epilepsy patients. Epilepsy Res. 2003, 55, 53-58.
26. Klein K, Hamer H, Reis J, [et al.]. Weight change in monozygotic twins treated with valproate. Obes Res. 2005, 13, 1330-1334.